U. S. stock futures edged higher on Friday as investors balanced escalating geopolitical tensions in the Middle East against encouraging corporate earnings from the
Latest News
Dow Jones futures: Market triggers sell signal; Apple earnings, Iran news, Fed meeting in focus
Apple, Amazon, Meta, Microsoft, SK Hynix are on tap with the Nasdaq breaking lower.
Salesforce, IBM share gains contribute to Dow’s 300-point climb
Led by strong returns for shares of Salesforce and IBM, the Dow Jones Industrial Average is climbing Friday morning. The Dow was most recently
Options Action: ‘Risk pivot’ level looms large
CNBC’s Oliver Renick joins ‘Closing Bell’ to talk markets reaching a key level for options traders. Got a confidential news tip? We want to
Dow Jones and S&P 500 Forecast: Oil, Tariffs and Yields Test Wall Street Rally
Dow Jones and S&P 500 face pressure from tariffs, rising oil prices and higher Treasury yields, while key support levels keep the broader bullish
American Express stock enters earnings with a $12 shock hiding in plain sight
This targets the bullish scenario where management’s forward guidance and credit/margin commentary drive a real upside move, while limiting damage if the stock only
CorVel Corporation CEO Sarah Scott Exercises Stock Options to Acquire 25,000 Shares
Stock Option Exercise Details. On July 1, 2026, Sarah Scott, serving as CEO and President of CorVel Corporation, exercised a non-qualified stock option to
S&P 500, Dow, Nasdaq end second week lower over elevated oil prices, chipmaker rout — PSKY, UBER, QCOM, VZ, INTC in focus
The S&P 500 ended 0.1% higher, while the Nasdaq 100 slipped 1.2% and the Dow Jones Industrial Average ended 0.5% higher. ・Qualcomm, the biggest
Buying stocks is hard: Five lessons for smarter investing
Still, buying is never easy. It is putting your hard-earned money at risk and stocks can go down, sometimes a lot. Most investors lament
Nektar Therapeutics Reports Vesting of 16,500 Stock Options for Chief R&D Officer Jonathan Zalevsky
Stock Option Vesting Details. Nektar Therapeutics recently announced that Jonathan Zalevsky, Chief R&D Officer, had his stock options vest on July 24, 2026. This